Cargando…

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction

Background: Vericiguat, a novel oral soluble guanylate cyclase stimulator, decreased the incidence of cardiovascular death and heart failure hospitalization in the cohort receiving triple therapy for heart failure with reduced ejection fraction. However, efficacy and optimal patient selection in rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Makiko, Imamura, Teruhiko, Kinugawa, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342475/ https://www.ncbi.nlm.nih.gov/pubmed/37445431 http://dx.doi.org/10.3390/jcm12134396

Ejemplares similares

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
por: Falco, Luigi, et al.
Publicado: (2023)

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
por: Hammer, Andreas, et al.
Publicado: (2023)

Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure
por: Nakamura, Makiko, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
por: Kassis-George, Hayah, et al.
Publicado: (2022)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
por: Alsumali, Adnan, et al.
Publicado: (2021)

Chronotype of Lung Fluid Levels in Patients with Chronic Heart Failure
por: Ueno, Yohei, et al.
Publicado: (2022)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure
por: Hori, Masakazu, et al.
Publicado: (2020)

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2022)

Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2023)

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021)

Optimal Heart Rate and Prognosis in Patients with Cardiac Amyloidosis
por: Izumida, Toshihide, et al.
Publicado: (2021)

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
por: Gandjour, Afschin
Publicado: (2022)

Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

How to consider target heart rate in patients with systolic heart failure
por: Izumida, Toshihide, et al.
Publicado: (2020)

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
por: Nakagaito, Masaki, et al.
Publicado: (2021)

Optimal Therapeutic Strategy Using Sacubitril/Valsartan in a Patient with Systolic Heart Failure and Chronic Kidney Disease - An Initial Case Report in Japan
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2016)

Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Successful Management of Osimertinib-Induced Heart Failure
por: Fukuo, Atsuko, et al.
Publicado: (2022)

How to Improve the Cardiac Function and Clinical Outcomes in Patients with Heart Failure with a Mid-range Ejection Fraction
por: Imamura, Teruhiko
Publicado: (2021)

Chronic heart failure: the role of di vericiguat
por: Caminiti, Giuseppe, et al.
Publicado: (2023)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Emerging concepts in heart failure management and treatment: focus on vericiguat
por: Kaplinsky, Edgardo, et al.
Publicado: (2023)

Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)

Optimization of pressure settings during adaptive servo-ventilation support using real-time heart rate variability assessment: initial case report
por: Imamura, Teruhiko, et al.
Publicado: (2017)

Vericiguat: A New Hope for Heart Failure Patients
por: Chiles, Raquel, et al.
Publicado: (2022)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cdtjuo7o739713vr6a6ddbqt4j